NASDAQ:WVE WAVE Life Sciences (WVE) Stock Price, News & Analysis $4.59 -0.08 (-1.71%) Closing price 09/11/2026 04:00 PM EasternExtended Trading$4.66 +0.07 (+1.53%) As of 09/11/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About WAVE Life Sciences Stock (NASDAQ:WVE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get WAVE Life Sciences alerts:Sign Up Key Stats Today's Range$4.56▼$4.7250-Day Range$4.59▼$6.3852-Week Range$4.56▼$21.73Volume2.20 million shsAverage Volume3.13 million shsMarket Capitalization$904.46 millionP/E RatioN/ADividend YieldN/APrice Target$22.31Consensus RatingModerate Buy Company Overview WAVE Life Sciences Ltd. (NASDAQ: WVE) is a biotechnology company focused on developing medicines that target RNA, the biological molecule that helps translate genetic information into proteins. The company uses its oligonucleotide chemistry and delivery technologies to pursue treatments for genetically defined diseases, including conditions affecting the liver, muscles and nervous system. WAVE’s research programs include RNA editing medicines designed to correct or modify disease-related genetic messages without permanently altering DNA. The company has also developed stereopure oligonucleotide technologies intended to improve the activity and tolerability of RNA-targeted therapies. Its pipeline has included investigational programs for alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and other rare diseases. Founded in 2012, WAVE Life Sciences conducts drug discovery and clinical development activities through operations in the United States and other international locations. The company’s programs are evaluated through clinical studies and collaborations with healthcare and research organizations as it works to advance RNA medicines for patients with serious genetic disorders. Paul Bolno has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More WAVE Life Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreWVE MarketRank™: WAVE Life Sciences scored higher than 60% of companies evaluated by MarketBeat, and ranked 395th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingWAVE Life Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on no strong buy ratings, 14 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialWAVE Life Sciences has a consensus price target of $22.31, representing about 386.1% upside from its current price of $4.59.Amount of Analyst CoverageWAVE Life Sciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about WAVE Life Sciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for WAVE Life Sciences are expected to decrease in the coming year, from ($1.11) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of WAVE Life Sciences is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of WAVE Life Sciences is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWAVE Life Sciences has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about WAVE Life Sciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.92% of the float of WAVE Life Sciences has been sold short.Short Interest Ratio / Days to CoverWAVE Life Sciences has a short interest ratio ("days to cover") of 5.49.Change versus previous monthShort interest in WAVE Life Sciences has recently increased by 0.50%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldWAVE Life Sciences does not currently pay a dividend.Dividend GrowthWAVE Life Sciences does not have a long track record of dividend growth. News and Social Media3.2 / 5News Sentiment1.14 News SentimentWAVE Life Sciences has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.89 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for WAVE Life Sciences this week, compared to 6 articles on an average week.Search InterestOnly 9 people have searched for WVE on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat Follows8 people have added WAVE Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, WAVE Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $132,476.00 in company stock.Percentage Held by Insiders24.30% of the stock of WAVE Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.73% of the stock of WAVE Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about WAVE Life Sciences' insider trading history. Receive WVE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for WAVE Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. WVE Stock News HeadlinesWAVE Life Sciences Ltd. (NASDAQ:WVE) Receives Consensus Rating of "Moderate Buy" from AnalystsSeptember 4, 2026 | americanbankingnews.comWave Life Sciences to Present at Cantor 2026 Global Healthcare ConferenceSeptember 3, 2026 | globenewswire.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.September 13 at 1:00 AM | Banyan Hill Publishing (Ad)WAVE Life Sciences (NASDAQ:WVE) Director Sells $23,222.64 in StockAugust 14, 2026 | insidertrades.comWave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma TakeoverAugust 13, 2026 | 247wallst.comWave Life Sciences: An Fairly Valued RNA OpportunityAugust 12, 2026 | seekingalpha.comWave Life Sciences Ltd. (WVE) Presents at Bank of America SMID Cap Virtual Conference TranscriptAugust 11, 2026 | seekingalpha.comWave Life Sciences Completes Redomiciliation to DelawareAugust 10, 2026 | finance.yahoo.comSee More Headlines WVE Stock Analysis - Frequently Asked Questions How have WVE shares performed this year? WAVE Life Sciences' stock was trading at $17.00 at the beginning of the year. Since then, WVE shares have decreased by 73.0% and is now trading at $4.59. How were WAVE Life Sciences' earnings last quarter? WAVE Life Sciences Ltd. (NASDAQ:WVE) released its quarterly earnings results on Thursday, July, 30th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by $0.04. The firm earned $2.27 million during the quarter, compared to analysts' expectations of $7.45 million. WAVE Life Sciences had a negative net margin of 309.73% and a negative trailing twelve-month return on equity of 50.36%. Read the conference call transcript. When did WAVE Life Sciences IPO? WAVE Life Sciences (WVE) raised $102 million in an IPO on Wednesday, November 11th 2015. The company issued 6,375,000 shares at a price of $15.00-$17.00 per share. Who are WAVE Life Sciences' major shareholders? WAVE Life Sciences' top institutional shareholders include Readystate Asset Management LP (2.40%), Squarepoint Ops LLC (1.29%), California State Teachers Retirement System (0.42%) and Newtyn Management LLC (0.11%). Insiders that own company stock include Ra Capital Management, LP, Plc Gsk, Chandra Vargeese, Paul Bolno, Gregory L Verdine, Kyle Moran, Chris Francis, Heidi L Wagner, Mark Corrigan, Ken Takanashi, Christian O Henry and Adrian Rawcliffe. View institutional ownership trends. How do I buy shares of WAVE Life Sciences? Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of WAVE Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that WAVE Life Sciences investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Intel (INTC) and Netflix (NFLX). Company Calendar Last Earnings7/30/2026Today9/13/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 WVE's financial health is in the Red zone, according to TradeSmith. WVE has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:WVE CIK1631574 Webwww.wavelifesciences.com Phone(656) 236-3388Fax617-949-2901Employees317Year Founded2012Price Target and Rating Average Price Target for WAVE Life Sciences$22.31 High Price Target$43.00 Low Price Target$12.00 Potential Upside/Downside+386.1%Consensus RatingModerate Buy Rating Score (0-4)2.81 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$204.38 million Net Margins-309.73% Pretax Margin-309.73% Return on Equity-50.36% Return on Assets-40.06% Debt Debt-to-Equity RatioN/A Current Ratio9.99 Quick Ratio9.99 Sales & Book Value Annual Sales$42.73 million Price / Sales21.17 Cash FlowN/A Price / Cash FlowN/A Book Value$3.10 per share Price / Book1.48Miscellaneous Outstanding Shares197,050,000Free Float149,165,000Market Cap$904.46 million OptionableOptionable Beta-1.30 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:WVE) was last updated on 9/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding WAVE Life Sciences Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share WAVE Life Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
